Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Role of cholinesterase inhibitors in dementia care needs rethinking.

Literature DB >> 16946340

Role of cholinesterase inhibitors in dementia care needs rethinking.

Anthony J Pelosi¹, Seamus V McNulty, Graham A Jackson.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2006 PMID： 16946340 PMCID： PMC1557932 DOI： 10.1136/bmj.38945.478160.94

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

9 in total

Review 1. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.

Authors: A Clegg; J Bryant; T Nicholson; L McIntyre; S De Broe; K Gerard; N Waugh
Journal: Health Technol Assess Date: 2001 Impact factor: 4.014

2. Drugs for Alzheimer's disease.

Authors: J T O'Brien; C G Ballard
Journal: BMJ Date: 2001-07-21

Review 3. Donepezil for dementia due to Alzheimer's disease.

Authors: J Birks; R J Harvey
Journal: Cochrane Database Syst Rev Date: 2006-01-25

4. Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers.

Authors: P J Neumann; K M Kuntz; J Leon; S S Araki; R C Hermann; M A Hsu; M C Weinstein
Journal: Med Care Date: 1999-01 Impact factor: 2.983

Review 5. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

Authors: E Loveman; C Green; J Kirby; A Takeda; J Picot; E Payne; A Clegg
Journal: Health Technol Assess Date: 2006-01 Impact factor: 4.014

6. Patient and caregiver characteristics and nursing home placement in patients with dementia.

Authors: Kristine Yaffe; Patrick Fox; Robert Newcomer; Laura Sands; Karla Lindquist; Kyle Dane; Kenneth E Covinsky
Journal: JAMA Date: 2002-04-24 Impact factor: 56.272

Review 7. Rivastigmine for Alzheimer's disease.

Authors: J Birks; V Iakovidou; M Tsolaki
Journal: Cochrane Database Syst Rev Date: 2000

Review 8. Galantamine for Alzheimer's disease and mild cognitive impairment.

Authors: C Loy; L Schneider
Journal: Cochrane Database Syst Rev Date: 2006-01-25

Review 9. Cholinesterase inhibitors for Alzheimer's disease.

Authors: J Birks
Journal: Cochrane Database Syst Rev Date: 2006-01-25

9 in total

13 in total

1. Role of cholinesterase inhibitors in dementia care: memory clinics and cholinesterase inhibitors have their place.

Authors: David J Jolley; Susan M Benbow
Journal: BMJ Date: 2006-09-16

2. Role of cholinesterase inhibitors in dementia care: NICE's economic analysis has limitations.

Authors: Richard J Phillips; Nick Bosanquet
Journal: BMJ Date: 2006-09-16

3. Curing and caring: the work of primary care physicians with dementia patients.

Authors: Ester Carolina Apesoa-Varano; Judith C Barker; Ladson Hinton
Journal: Qual Health Res Date: 2011-06-17

4. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.

Authors: Denis Getsios; Steve Blume; K Jack Ishak; Grant D H Maclaine
Journal: Pharmacoeconomics Date: 2010 Impact factor: 4.981

5. Defining treatment response to donepezil in Alzheimer's disease: responder analysis of patient-level data from randomized, placebo-controlled studies.

Authors: Alistair Burns; Andrew Yeates; Latif Akintade; Megan Del Valle; Richard Y Zhang; Elias M Schwam; Carlos A Perdomo
Journal: Drugs Aging Date: 2008 Impact factor: 3.923

Review 6. NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?

Authors: Denis Getsios; Kristen Migliaccio-Walle; Jaime J Caro
Journal: Pharmacoeconomics Date: 2007 Impact factor: 4.981